Viatris Stock: Is Wall Street Bullish or Bearish?

Viatris Inc. (VTRS) is a global healthcare company valued at a market cap of $12 billion. It focuses on providing affordable medicines across a wide range of therapeutic areas, including cardiovascular, infectious disease, oncology, immunology, and central nervous system disorders. The Pennsylvania-based company offers both branded and generic drugs, biosimilars, and over-the-counter products, serving more than 165 countries and territories. 

Shares of this global healthcare giant have considerably underperformed the broader market over the past year. VTRS has declined 9.4% over this time frame, while the broader S&P 500 Index ($SPX) has rallied 19.6%. The gap has widened in 2025, with VTRS down 15.4% year-to-date compared to a 16.5% gain for the $SPX.